Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgeralds financial statements. Below is selected financial information for the fiscal year ended June 30, 2014.

FITZGERALD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2014
Long-term debt
Notes payable,9%	$1,101,000
8% convertible bonds payable	5,039,000
9% bonds payable	6,067,000
Total long-term debt	$12,207,000
Shareholders equity
Preferred stock,6% cumulative, $58par value,106,300shares authorized,26,575shares issued and outstanding	$1,541,350
Common stock, $1 par,10,052,000shares authorized,1,005,200shares issued and outstanding	1,005,200
Additional paid-in capital	4,016,000
Retained earnings	6,001,400
Total shareholders equity	$12,563,950

The following transactions have also occurred at Fitzgerald.

1.	Options were granted on July 1, 2013, to purchase204,900shares at $16per share. Although no options were exercised during fiscal year 2014, the average price per common share during fiscal year 2014 was $20per share.
2.	Each bond was issued at face value. The8% convertible bonds will convert into common stock at58shares per $1,000bond. The bonds are exercisable after 5 years and were issued in fiscal year 2013.
3.	The preferred stock was issued in 2013.
4.	There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2014.
5.	The1,005,200shares of common stock were outstanding for the entire 2014 fiscal year.
6.	Net income for fiscal year 2014 was $1,547,000, and the average income tax rate is40%.

For the fiscal year ended June 30, 2014, calculate the following for Fitzgerald Pharmaceutical Industries.(Round answers to 2 decimal places, e.g. $2.45.)

(a)Basic earnings per share.

Basic earnings per share

$

(b)Diluted earnings per share.

Diluted earnings per share

$